▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3962 by analyst upside · 2026-09-28
SGHT
Sight Sciences, Inc.
Healthcare · Market Cap $492M · P/E 0x
ANALYST PRICE TARGET
+0.8%
implied upside to consensus target
Current Price $8.93
Consensus Target $9.0
Bull Target $12.0
Bear Target $8.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
1
Sell
0
52-Week Low $3.19
52-Week High $9.24
YTD Return +19.4%
FUNDAMENTALS
Market Cap $492M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.55
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $83M
Profit Margin -35.7%
52-WEEK RANGE
52-Week Low $3.19
52-Week High $9.24
Current Price $8.93
Bear Target $8.0
Bull Target $12.0
● Now $8.93 ● Target $9.0
TRADING DATA
Avg Volume 228K
YTD Return +19.4%
Analyst Count 5
Consensus Buy
Upside to Target +0.8%
Last Updated 2026-09-28

ANALYST SUMMARY

Sight Sciences, Inc. (SGHT) is currently trading at $8.93 with a Wall Street consensus price target of $9.0, implying potential upside of 0.8% over the next 12 months. 5 analysts currently cover SGHT, with a consensus rating of Buy - 80% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $8.0.

SGHT operates in the Healthcare sector with a market capitalisation of $492M. The stock is up 19.4% year-to-date and is currently trading near the upper end of its 52-week range of $3.19 – $9.24.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for SGHT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-08-06 33% win rate (6 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-07-08 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-05-28 Building track record
UBS - Reiterated
Buy → Buy 2026-03-06 33% win rate (6 calls)
Citigroup - Reiterated
Neutral → Neutral 2026-03-06 Building track record
Stifel - Reiterated
Buy → Buy 2026-03-02 Building track record
Piper Sandler ↑ Upgrade
Neutral → Overweight 2026-01-05 14% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2025-12-23 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
57
out of 100
Coverage depth
14/30
Consensus clarity
21/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →